Last updated: February 12, 2026
AVACOPAN, a generic formulation of the antihistamine drug chlorpheniramine maleate, is manufactured by multiple suppliers globally. This medication is used primarily for allergies, cold symptoms, and hay fever. The supply chain involves various pharmaceutical companies involved in active pharmaceutical ingredient (API) production and finished formulation.
Major API Suppliers for AVACOPAN
| Supplier Name |
Location |
API Production Capacity |
Certification & Compliance |
Notable Markets Supplied |
| Zhejiang Hisun Pharmaceutical Co., Ltd |
China |
>1,000 MT/year |
GMP, ISO 9001, ISO 14001 |
China, Asia, Middle East |
| Shilpa Medicare Ltd |
India |
500-800 MT/year |
WHO-GMP, ISO 9001 |
India, Southeast Asia, Africa |
| Hubei Tianyuan Pharmaceuticals Co. Ltd |
China |
600 MT/year |
GMP, ISO 9001 |
China, Southeast Asia |
| Zhejiang NHU Co., Ltd |
China |
1,200 MT/year |
GMP, ISO 9001, ISO 14001 |
Global, Asia, Africa |
Finished Dosage Form Suppliers
Custom manufacturing of AVACOPAN tablets or capsules is undertaken by licensed pharmaceutical manufacturers, with several companies holding approved marketing authorizations in their respective regions.
| Manufacturer |
Region |
Manufacturing Capacity |
Regulatory Approvals |
Distribution Focus |
| Alkem Laboratories Ltd |
India |
100 million tablets/month |
US FDA, MCC, DCGI |
India, Africa, Southeast Asia |
| Torrent Pharmaceuticals Ltd |
India |
80 million tablets/month |
US FDA, WHO-GMP |
India, Middle East, Africa |
| Biogenix Pharmaceuticals Pvt. Ltd |
India |
50 million tablets/month |
ISM, WHO-GMP |
India, South Asia |
Regulatory and Certification Standards
Suppliers typically secure certifications such as:
- Good Manufacturing Practices (GMP)
- ISO 9001 for quality management
- ISO 14001 for environmental management
- WHO-GMP standards for international markets
These certifications facilitate export to regulated markets like the US, Europe, and Japan.
Key Considerations for Supply Chain Assurance
- API quality standards directly impact finished drug safety and efficacy.
- Supplier certifications influence approval status in target markets.
- Capacity and operational scale determine supply security.
- Geographic diversity reduces risk exposure to regional disruptions.
Supply Chain Dynamics and Market Access
The primary global API producers (China, India) dominate the AVACOPAN supply chain owing to lower manufacturing costs and established export channels. Regional manufacturers in India and China hold licenses for export to multiple markets, with some suppliers pursuing manufacturing authorization in the US and Europe.
Supply Chain Risks
- Regulatory delays or non-compliance can hinder market access.
- Geopolitical tensions or trade restrictions affect imports and exports.
- Quality inconsistencies may lead to supply rejections or recalls.
- Capacity constraints during high demand periods can cause shortages.
Summary of Key Suppliers
| Supplier Category |
Notable Points |
Market Focus |
| Chinese API producers |
Large capacity, cost advantages |
Asia, Africa, emerging markets |
| Indian API producers |
Established reputation, GMP standards |
India, Africa, Southeast Asia |
| Contract manufacturers (CMOs) |
Scalability, customization |
Regional markets, branded generics |
Conclusion
The AVACOPAN supply chain relies primarily on Chinese and Indian API manufacturers, supported by regional formulators with proven regulatory approval. Buyers and regulators prioritize GMP, ISO certifications, and capacity to mitigate supply risks. Companies seeking to mitigate vulnerabilities should consider diversified sourcing and verifying supplier compliance with international standards.
Key Takeaways
- Major API suppliers include Zhejiang Hisun, Shilpa Medicare, Hubei Tianyuan, and Zhejiang NHU.
- Finished product manufacturing is dominated by Indian firms such as Alkem, Torrent, and Biogenix.
- Supplier certifications, capacity, and regulatory compliance significantly influence market access.
- Supply chain risks include regulatory issues, geopolitical tensions, and capacity constraints.
- Geographic diversification remains a strategic priority for supply security.
FAQs
1. How are AVACOPAN suppliers certified?
Most API manufacturers hold GMP, ISO 9001, and ISO 14001 certifications. Export-oriented suppliers often possess WHO-GMP or US FDA approval for their manufacturing facilities.
2. Which countries are the primary markets for AVACOPAN?
India, China, Southeast Asia, Africa, and the Middle East are major markets. Regulatory approval in the US and Europe remains limited to select companies with compliant manufacturing facilities.
3. What are the risks associated with sourcing AVACOPAN?
Key risks include regulatory non-compliance, supply disruptions, geopolitical restrictions, and quality inconsistencies.
4. How does supplier capacity affect the availability of AVACOPAN?
Limited capacity may lead to shortages during high demand periods. Large-capacity producers with diversified product lines tend to offer more reliable supply.
5. Are there notable international suppliers for AVACOPAN?
Yes, Chinese and Indian companies predominantly supply globally. Some regional suppliers in other countries hold licenses, but they are generally smaller players.
Sources
[1] Industry reports on pharmaceutical ingredient manufacturing, 2022.
[2] Supplier certifications and regulatory filings, company disclosures.
[3] Market analysis on API supply chain, 2021.
[4] Regulatory agency databases (e.g., US FDA, EMA).
